ARS Pharmaceuticals
SPRY
SPRY
92 hedge funds and large institutions have $369M invested in ARS Pharmaceuticals in 2023 Q2 according to their latest regulatory filings, with 31 funds opening new positions, 32 increasing their positions, 19 reducing their positions, and 27 closing their positions.
New
Increased
Maintained
Reduced
Closed
more call options, than puts
Call options by funds: $ | Put options by funds: $
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more first-time investments, than exits
New positions opened: | Existing positions closed:
more capital invested
Capital invested by funds: $ → $
3% more funds holding
Funds holding: 89 → 92 (+3)
1.52% more ownership
Funds ownership: 56.59% → 58.11% (+1.5%)
33% less funds holding in top 10
Funds holding in top 10: 3 → 2 (-1)
Holders
92
Holding in Top 10
2
Calls
$7.92M
Puts
$3.22M
Top Buyers
| 1 | +$7.65M | |
| 2 | +$6.37M | |
| 3 | +$3.64M | |
| 4 |
Two Sigma Investments
New York
|
+$3.21M |
| 5 |
SAM
Sectoral Asset Management
Montreal,
Quebec, Canada
|
+$3.1M |
Top Sellers
| 1 | -$9.48M | |
| 2 | -$4.57M | |
| 3 | -$3.22M | |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
-$2.84M |
| 5 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
-$1.72M |